StockData
Prime Medicine, Inc. logo

Prime Medicine, Inc. (PRME) stock

PRMENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$3.84−0.35 (-8.35%)

Close on Nov 17, 2026Market cap $696.49MP/E –Yield –

Prime Medicine operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Prime Medicine's operating cash flow for the twelve months ending Jun 30, 2026 was -$156.05M. For fiscal 2025 it was -$162.56M. The highest annual figure on record is -$5.54M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$162.56M–
FY2024Dec 31, 2024-$122.87M–
FY2023Dec 31, 2023-$165.41M–
FY2022Dec 31, 2022-$131.83M–
FY2021Dec 31, 2021-$34.08M–
FY2020Dec 31, 2020-$5.54M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$41.05M–
Q1 FY2026Mar 31, 2026-$42.71M–
Q4 FY2025Dec 31, 2025-$37.26M-329.3%
Q3 FY2025Sep 30, 2025-$35.04M–
Q2 FY2025Jun 30, 2025-$41.41M–
Q1 FY2025Mar 31, 2025-$48.86M–
Q4 FY2024Dec 31, 2024$16.25M–
Q3 FY2024Sep 30, 2024-$25.91M–
Q2 FY2024Jun 30, 2024-$45.49M–
Q1 FY2024Mar 31, 2024-$67.71M–
Q4 FY2023Dec 31, 2023-$43.86M–
Q3 FY2023Sep 30, 2023-$39.17M–
Q2 FY2023Jun 30, 2023-$40.82M–
Q1 FY2023Mar 31, 2023-$41.56M–
Q4 FY2022Dec 31, 2022-$30.71M–
Q3 FY2022Sep 30, 2022-$30.10M–
Q2 FY2022Jun 30, 2022-$20.22M–
Q1 FY2022Mar 31, 2022-$50.79M–
Q4 FY2021Dec 31, 2021-$13.19M–

More Prime Medicine figures

See a number that looks wrong?